Global Leading Market Research Publisher QYResearch announces the release of its latest report “Industrial Hemp – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Industrial Hemp market, including market size, share, demand, industry development status, and forecasts for the next few years.
Consumer packaged goods companies, pharmaceutical manufacturers, and cosmetics brands face a growing challenge: meeting rising consumer demand for natural, plant-based wellness ingredients while navigating complex and rapidly evolving regulations. Traditional botanical extracts often lack the consistent quality, efficacy, and legal clarity that brand owners require for scalable product development. Industrial Hemp directly addresses this opportunity. The industrial hemp counted in this report refers to the original plants of the genus Cannabis and their extracted products with a tetrahydrocannabinol (THC) content of less than 0.3 percent (percentage by dry matter weight). Cannabis is a non-psychoactive compound increasingly used in health and wellness, cosmetics, food and beverage, and pharmaceutical products. The global cannabis market has grown rapidly in recent years due to increasing consumer awareness, evolving regulations, and demand for natural remedies. North America dominates the market, but Asia-Pacific and Europe are emerging as high-potential regions.
The global market for Industrial Hemp was estimated to be worth USD 411 million in 2024 and is forecast to a readjusted size of USD 1040 million by 2031 with a CAGR of 14.3% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4846945/industrial-hemp
Core Market Trends Driving Growth
Trend One: Expansion of Legalization Worldwide
More countries and states are legalizing hemp-derived CBD for medical and wellness uses. The 2018 U.S. Farm Bill federally legalized industrial hemp and its derivatives, setting the stage for market expansion. Similar regulatory changes in Europe (EU Novel Food regulations), Canada (Cannabis Act), and emerging legalization in parts of Asia-Pacific (Thailand, South Korea) and Latin America have progressively opened new markets. According to our mid-2025 analysis, over 50 countries have now legalized hemp-derived CBD for some applications, up from approximately 30 in 2020.
Trend Two: Product Diversification
CBD is being integrated into various products such as gummies, capsules, beverages, skincare, and pet care. This diversification expands the addressable market beyond traditional tinctures and oils. The beverages segment, including CBD-infused sparkling water, teas, and functional drinks, is the fastest-growing category at approximately 25 percent CAGR, driven by consumer preference for convenient, familiar consumption formats.
Trend Three: Growth in E-commerce Channels
Online platforms have become key distribution channels, especially post-COVID-19. Direct-to-consumer brands selling CBD products through proprietary websites, combined with third-party marketplaces (Amazon remains restrictive, but specialty platforms have emerged), have enabled rapid scaling without traditional retail distribution. Our analysis indicates that e-commerce accounts for approximately 45 percent of CBD product sales in North America, up from 25 percent in 2019.
Trend Four: Rising Investment in Research and Development
Companies are investing in clinical trials, product innovation, and purity enhancement. Pharmaceutical companies are investigating CBD for epilepsy (Epidiolex, FDA-approved), anxiety, chronic pain, and sleep disorders. Cosmetic brands are developing CBD-infused topicals with claims around anti-inflammatory and antioxidant properties. Food and beverage companies are formulating CBD products with enhanced bioavailability through nano-emulsion technology.
Market Barriers and Challenges
Despite strong growth potential, the Industrial Hemp market faces significant barriers. Regulatory uncertainty and variability across jurisdictions create compliance complexity. Differences in legality, labeling requirements, and THC content limits (0.2% in Europe versus 0.3% in the United States) complicate cross-border commerce.
Quality control and standardization issues persist due to lack of uniform manufacturing standards. Inconsistent product quality, including variability in CBD concentration, presence of contaminants (heavy metals, pesticides, residual solvents), and inaccurate labeling, undermine consumer trust. The industry is gradually adopting Good Manufacturing Practices (GMP) certification and third-party testing.
Public misconceptions and stigma associated with marijuana hamper broader market acceptance in some regions. Consumer education remains a significant investment area for brand owners.
High cost of extraction and purification technologies, such as supercritical CO₂ extraction, requires substantial capital investment and technical expertise, creating barriers to entry for smaller producers.
Industry Layered Analysis: CBD Oil versus CBD Crystal
A critical analytical distinction exists between CBD oil (full-spectrum, broad-spectrum, and isolate in liquid form) and CBD crystal (pure crystalline isolate), each serving different applications and customer segments.
CBD Oil dominates the market with approximately 70 percent revenue share. Full-spectrum oil contains additional cannabinoids (CBG, CBN, trace THC) and terpenes, providing the “entourage effect” believed to enhance therapeutic benefits. Broad-spectrum oil offers similar benefits without THC. CBD oil is preferred for tinctures, capsules, and beverage formulations. The oil segment grows at 14.0 percent CAGR.
CBD Crystal (isolate powder) accounts for approximately 30 percent market share. Isolate contains 99+ percent pure CBD with no other cannabinoids or terpenes. Crystal form offers formulation flexibility for edibles, topicals, and pharmaceuticals where precise dosing and absence of flavor/odor are required. Isolate commands slightly lower pricing than full-spectrum oil (approximately 10 to 15 percent discount) but has longer shelf stability. The crystal segment grows at 15.0 percent CAGR, driven by pharmaceutical and food formulation demand.
Application Deep Dive: Medical, Food & Beverage, Cosmetics, and Other
Medical and Pharmaceutical applications represent the largest segment at approximately 40 percent of market revenue, including prescription drugs (Epidiolex), nutraceuticals, and wellness supplements. This segment is the fastest-growing at 16 percent CAGR, driven by clinical research and regulatory approvals.
Food and Beverage accounts for approximately 30 percent of revenue, including functional beverages, edibles (gummies, chocolates), and culinary products. Growth is driven by consumer acceptance of CBD as a food ingredient and innovation in formulation.
Cosmetics represents approximately 20 percent of revenue, including skincare, serums, balms, and beauty products. The topical application segment has lower regulatory barriers than ingestible products, accelerating market entry.
Other applications including pet care (approximately 10 percent) represent the emerging frontier, with CBD pet products for anxiety, pain, and wellness gaining consumer acceptance.
User Case Study: Beverage Brand CBD Integration
A national beverage brand, whose identity remains confidential under client agreement, launched a line of CBD-infused sparkling waters across 15,000 retail locations in 2025. The brand source CBD isolate from certified suppliers, formulated with nano-emulsion technology achieving 90 percent bioavailability (compared with 10-20 percent for standard oil formulations). The product line exceeded first-year sales projections by 40 percent, achieving USD 25 million in revenue. Key success factors included clear labeling (25 mg CBD per can), third-party testing verification displayed via QR code, and retail partnerships with natural food chains. The brand has expanded to CBD-infused teas and energy shots.
Market Segmentation and Competitive Landscape
The Industrial Hemp market is segmented by type into CBD oil (70 percent revenue share) and CBD crystal (30 percent). CBD crystal is the faster-growing segment at 15.0 percent CAGR.
By application, the market is segmented into medical and pharmaceutical (40 percent), food and beverage (30 percent), cosmetics (20 percent), and other including pet care (10 percent). Medical and pharmaceutical is the fastest-growing at 16 percent CAGR.
Key players include Kazmira (United States), KND Labs (United States), Aurora Cannabis (Canada), Canopy Growth Corporation (Canada), Endoca (Denmark), Charlotte‘s Web CBD (United States), CV Sciences (United States), Sequoya (United States), Mile High Labs (United States), EcoGen Biosciences (United States), Medical Marijuana, Inc. (United States), Yunnan Hempson Bio-Tech (China), and Tengchong Chenguang Yunma Biotechnology (China). The market exhibits moderate fragmentation, with North American players dominating global supply, though Chinese producers are gaining share in isolate manufacturing.
Original Industry Observation and Outlook
Unlike the broader botanical extract market where Chinese manufacturers dominate, the industrial hemp market remains concentrated in North America and Europe due to regulatory proximity to major consumer markets. Our exclusive analysis indicates that U.S. and Canadian producers account for approximately 65 percent of global CBD oil revenue, with Chinese producers focusing on isolate for export.
The most underserved market segment is water-soluble CBD formulations for beverage and functional food applications. Current products suffer from instability, poor bioavailability, and off-flavors. We project that advanced nano-emulsion and liposomal technologies will grow at 20 percent CAGR through 2031, capturing 25 percent of the food and beverage segment.
Additionally, the convergence of industrial hemp with pharmaceutical drug development represents a structural shift. Phase III clinical trials for CBD in anxiety disorders, schizophrenia, and substance use disorders are ongoing; positive results would dramatically expand the medical addressable market. We project that pharmaceutical-grade CBD will represent 30 percent of market revenue by 2029, up from 10 percent in 2025.
Contact Us
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
